Xanthohumol microbiome and signature in adults with Crohn’s disease (the XMaS trial): a protocol for a phase II triple-masked, placebo-controlled clinical trial

BACKGROUND: Xanthohumol (XN), a bioactive flavonoid from Humulus lupulus with anti-inflammatory properties, has potential benefits for patients with Crohn’s disease (CD), a type of inflammatory bowel disease. We recently completed and published results of a placebo-controlled phase I clinical trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Langley, Blake O., Ryan, Jennifer Joan, Phipps, John, Buttolph, Lita, Bray, Brenna, Aslan, Joseph E., Metz, Thomas O., Stevens, Jan F., Bradley, Ryan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587656/
https://www.ncbi.nlm.nih.gov/pubmed/36273173
http://dx.doi.org/10.1186/s13063-022-06782-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587656/
https://www.ncbi.nlm.nih.gov/pubmed/36273173
http://dx.doi.org/10.1186/s13063-022-06782-z

Ejemplares similares